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ABSTRACT 3 
Anaemia is a condition in which the number of red cells necessary to meet the body's physiological 4 
requirements is insufficient. Iron deficiency anaemia (IDA) and the anaemia of chronic disease (ACD) 5 
are the two most common causes of anaemia worldwide1; iron homeostasis plays a pivotal role in 6 
the pathogenesis of both diseases. An understanding of how iron studies can be used to distinguish 7 
between these diseases is therefore essential, not only for diagnosis but also in guiding 8 
management. This review will primarily focus on IDA and ACD; however iron overload in anaemia 9 
will also be briefly discussed. 10 
 11 
IRON HOMEOSTASIS 12 
The average human adult contains approximately 3 to 4g iron2. There is no excretory system for iron 13 
(aside from blood loss and mucosal shedding - which is not regulated by homeostasis) so absorption 14 
of iron from the gastrointestinal system is tightly controlled.  15 
Iron absorption into the enterocyte occurs primarily in the terminal duodenum through the divalent 16 
metal transporter (DMT1)3. Export of iron from the enterocyte is through the basolateral membrane 17 
by ferroportin-14. Ferroportin-1 is also highly expressed at sites involved in iron transfer including 18 
macrophage membranes and the sinusoidal surfaces of hepatocytes5.  19 
Once iron is released from the enterocyte, it is transported to sites of usage and storage by 20 
transferrin2. Transferrin is a 75-80 kDA glycosylated protein that can carry up to two ferric ions; 21 
under physiological conditions around 30-40% of the iron binding capacity of transferrin is used in6. 22 
Transferrin then delivers the bound iron through transferrin receptor-1 (TfR1) to the sites of usage 23 
and storage; TfR1 mediated iron import is the main pathway used by erythrocytes and hepatocytes7. 24 
Iron transport into the macrophages of the reticuloendothelial system (RES) is primarily through 25 
erythrophagocytosis of senescent red blood cells6. 26 
Free iron is cytotoxic; if it is not immediately utilised after internalisation it will associate with 27 
ferritin, the main iron storage protein in the body8. The main site for iron storage is within the 28 
macrophages of the reticuloendothelial system (particularly of the liver,  spleen and bone marrow) 29 
and hepatocytes6. Export of iron from sites of storage is through ferroportin-1. 30 
Regulation of iron homeostasis is mainly via iron regulatory proteins (IRP)/iron responsive elements 31 
(IRE) and hepcidin. The former control uptake and storage of iron whilst the latter regulates iron 32 
export. Hepcidin plays a central role in iron homeostasis through its effect on ferroportin-1; after 33 
hepcidin binds to ferroportin-1, ferroportin-1 is internalised and degraded by lysosomes; the overall 34 
effect is to decrease ferroportin-1 expression and block iron export9. 35 
It is beyond the remit of this review to fully cover iron homeostasis, a recent review by Tomas Ganz2 36 
provides a comprehensive overview of this topic.  37 
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IRON STUDIES 38 
Iron studies are a panel of tests used to assess the amount of circulating iron and storage iron. These 39 
tests should be interpreted together. Below is a summary of the routine iron studies performed in 40 
most laboratories. 41 
Ferritin 42 
As the main iron storage protein in the body, the majority of ferritin is intracellular. However, a 43 
soluble form is found in the blood and can be assayed10.  44 
Ferritin concentrations vary by age and gender. From adolescence, males have higher values than 45 
females, a trend that persists into late adulthood. In women, ferritin concentrations remain 46 
relatively low until menopause and then rise11. In both sexes, ferritin increases from around 70 years 47 
of age12. 48 
A ferritin concentration <15μg/L in adults13 is almost always diagnostic of iron deficiency. An 49 
elevated ferritin may reflect iron overload; however ferritin is an acute phase protein, so may also be 50 
increased in liver disease, malignancy, infection and inflammation14. Therefore, a normal ferritin 51 
concentration alone does not necessarily exclude iron deficiency. 52 
Serum iron 53 
Serum iron is a measure of the amount of iron bound to transferrin in the plasma. Only a small 54 
proportion of the body's iron is bound to transferrin at any one time 15. There is a rapid turnover of 55 
transferrin-bound iron and circulating iron concentration can be affected by dietary intake; as a 56 
result there is significant variation in iron concentration within each day and between days16. For this 57 
reason, assessment of serum iron alone provides little helpful clinical information.  58 
Total Iron Binding Capacity (TIBC) / Transferrin 59 
TIBC is an assay which determines the amount of iron that can be bound to unsaturated transferrin 60 
i.e. the total number of transferrin binding sites per unit volume of plasma or serum. Historically, it 61 
was assessed by adding an excess of iron to plasma and measuring the amount of iron retained17. 62 
Therefore TIBC is a proxy measure of transferrin. 63 
Unlike serum iron, TIBC does not have rapidly changing concentrations in the plasma. However it is 64 
not a useful marker of early iron deficiency as values do not change until stores are depleted18.  65 
Transferrin is the transporter protein for iron and its concentration can be determined by 66 
immunological methods18. Both TIBC and transferrin rise in iron deplete states and fall in 67 
inflammatory and iron overload disorders. 68 
Transferrin saturation 69 
This is derived by dividing serum iron by TIBC. As the name suggests, it is the percentage of 70 
transferrin bound to iron. In iron deplete states the amount of iron is reduced and therefore th e 71 
transferrin saturation will be reduced (and vice versa). A transferrin saturation of <15% in 72 
association with an elevated TIBC is indicative of iron deficiency anaemia. A transferrin saturation of 73 
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>45% is suggestive of iron overload and will usually require further investigation19. As previously 74 
mentioned, the variation in plasma concentration of iron is considerable, and therefore there will be 75 
daily variation in the transferrin saturation; as a result transferrin saturation must be interpreted 76 
alongside other iron studies. 77 
 78 
IRON DEFICIENCY ANAEMIA 79 
Iron deficiency anaemia is due to the lack of sufficient iron to form normal red blood cells ; it is the 80 
most common cause of anaemia worldwide1. Iron deficiency may be the result of blood loss, 81 
inadequate dietary intake or malabsorption. The gold standard for diagnosing iron deficiency is the 82 
absence of stainable iron on bone marrow biopsy; however this is impractical and iron deficiency is 83 
usually assessed by laboratory parameters on a peripheral blood sample. 84 
Laboratory diagnosis of iron deficiency anaemia 85 
Full blood count (FBC) and blood film 86 
By WHO criteria, anaemia is defined as a haemoglobin concentration (Hb) of <120g/L in a female or 87 
<130g/L in a male13. In the early stages of iron deficiency, haematopoiesis is not affected; as stores 88 
diminish further, the red cells become microcytic first and then hypochromic before the Hb falls. As 89 
well as microcytosis and hypochromia, the blood film may feature poikilocytosis (variation in shape, 90 
including pencil cells) and anisocytosis (variation in size)20. Microcytosis is reflected in the FBC as a 91 
reduction in the mean cell volume (MCV) and hypochromia as a reduction in the mean corpuscular 92 
haemoglobin concentration (MCHC). 93 
Iron Studies 94 
Hepcidin feedback is regulated by concentrations of iron; in iron deplete states, circulating 95 
concentrations of this hormone fall21. As hepcidin falls, ferroportin expression increases, leading to 96 
increased absorption of iron from enterocytes and increased iron export from storage cells. The 97 
IRP/IRE system also works to reduce the conversion of cytosolic iron into ferritin. Lastly, in order to  98 
optimise delivery of exported iron to areas of high demand, the production of transferrin is 99 
upregulated in the liver.  100 
Iron studies can reflect this physiological response. Circulating transferrin and TIBC are elevated. 101 
Serum iron falls; the relative decrease in supply compared to demand reduces the circulating pool. 102 
Transferrin saturation is reduced (typically <15%) due to increased TIBC and reduced serum iron. The 103 
increased export of iron from stores and decreased ferritin production lead to a fall in circulating 104 
ferritin; a concentration of <15μg/L is diagnostic of iron deficiency13. 105 
Although a low serum ferritin is both a highly specific and sensitive marker of iron deficiency, a 106 
normal ferritin can be falsely reassuring. As previously discussed, ferritin may rise with advancing 107 
age and inflammation, therefore diagnosing iron deficiency in these states can be challenging; 108 
however a ferritin concentration above 100μg/L is unlikely to be associated with iron deficiency22.  109 
The British Society of Gastroenterology suggests that the threshold for diagnosing iron deficiency 110 
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should be raised to a serum ferritin concentration of 50μg/L in people who have comorbidities23. 111 
Table 1 summarises these changes. 112 
There are assays which can be helpful in diagnosing iron deficiency in cases when it is not clear from 113 
conventional iron studies; these are discussed below. 114 
Soluble transferrin receptor (sTfR) 115 
sTfR results from the proteolysis of TfR and occurs following the binding of transferrin to Tf R, this 116 
produces monomers that are measurable in plasma or serum. The concentration of sTfR is therefore 117 
an indirect measure of total TfR24. TfR mediated iron import is the main pathway used by 118 
erythrocytes and hepatocytes; most TfRs are located on erythroid progenitors25. As a result sTfR 119 
concentration is believed to reflect erythroid turnover and is determined by erythroid proliferation 120 
rate and iron demand; sTfR concentrations will increase in iron deficiency26. Concentrations can also 121 
be increased in other high erythroid turnover states such as haemolytic anaemia and thalassaemia27.  122 
Unlike ferritin, sTfR is not an acute phase reactant, so serum concentrations do not rise in 123 
inflammatory states; therefore sTfR can be useful in diagnosing iron deficiency in such cases. In 124 
addition, sTfR/log ferritin index can be useful in diagnosing early iron deficiency and may have a 125 
higher sensitivity and specificity than sTfR alone28.  126 
sTfR is not a widely available assay. There is no uniform standard for measuring serum concentration 127 
or a universally established reference range. Therefore, whilst this may eventually be useful in 128 
determining iron status, validation is still necessary in population studies27. 129 
Zincprotoporphyrin (ZPP) 130 
In the last step of haemoglobin production, ferrous protoporphyrin is combined with globin to make 131 
haemoglobin. When there is a lack of iron, zinc replaces iron to produce zinc protoporphyrin. The 132 
normal ratio of iron to zinc in protoporphyrin is approximately around 30000:1, but ZPP will increase 133 
to measurable concentrations with progressive iron deficiency18. Currently this assay is not widely 134 
available but could be considered when conventional iron studies are not diagnostic. 135 
 136 
ANAEMIA OF CHRONIC DISEASE 137 
Anaemia of chronic disease (ACD) is the second most common cause of anaemia worldwide1; it was 138 
first identified in 1962 after studies on anaemia associated with infection29. ACD is expected to 139 
become more prevalent in the future as the number of elderly patients with chronic inflammatory 140 
conditions rises.  141 
A variety of clinical conditions can lead to ACD such as infection, inflammatory disorders (including 142 
inflammatory bowel disease and rheumatological conditions) and malignancy; these three causes 143 
account for 75% of cases30. ACD is immune driven. Cytokines induced by activated leucocytes exert 144 
multiple effects that contribute to the fall in haemoglobin; these include changes in iron 145 
homeostasis, erythropoietic activity, erythropoietin production and the life span of erythrocytes1.  146 
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A particular case of ACD is the anaemia of chronic renal failure. This is mediated by a decrease in 147 
circulating erythropoietin, which leads to a reduction in erythropoietic activity; this anti-proliferative 148 
effect is enhanced by accumulating uraemic toxins31. In patients with end stage disease, chronic 149 
inflammation has also been shown to correlate with the degree of anaemia32. The activation of 150 
immune cells may stem from repeated infection and/or contact activation from dialysis membranes. 151 
In these patients, the changes of iron homeostasis mirror those found in ACD1.  152 
The diagnosis of ACD can be challenging and is perhaps best explained in conjunction with the 153 
pathophysiological mechanisms underlying this disease. 154 
 155 
Dysregulation of iron homeostasis and its effect on laboratory markers 156 
Disturbance of iron homeostasis is a hallmark of ACD and is driven by inflammatory cytokines. 157 
There is an increase in interferon-ϒ (IFN-ϒ), tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), 158 
interleukin-6 (IL-6) and interleukin-10 (IL-10)1. IL-6 and lipopolysaccharide (endotoxin found on the 159 
outer membrane of gram negative bacteria) are strong inducers of hepatic hepcidin production33, 160 
this results in reduced ferroportin-1 expression and sequestration of iron within the enterocytes, 161 
hepatocytes and macrophages9. Iron import is unregulated in the macrophages by increased DMT-1 162 
expression (mediated by IFN-ϒ and lipopolysacharide), upregulation of TfR expression (mediated by 163 
IL-10) and lastly phagocytosis of senescent erythrocytes, a process which is enhanced by TNF-α 164 
mediated damage of erythrocyte membranes1. Lastly, TNF-α, IL-1, IL-6 and IL-10 all induce ferritin 165 
expression and stimulate the storage of iron6.  166 
The overall effect is increased iron storage, particularly in the macrophages, and decreased 167 
availability of iron which ultimately leads to iron restricted erythropoiesis34. This can be assessed by 168 
laboratory markers. 169 
Full blood count (FBC) and blood film 170 
ACD varies in severity but patients typically present with mild (Hb >100g/L) or moderate (Hb 85-171 
100g/L) reductions in haemoglobin concentrations35.  Microscopically, the erythrocytes are usually 172 
normocytic and normochromic.  Concurrent haematinic deficiencies, haemoglobinopathies and the 173 
underlying disease can all affect the red cell indices and blood film features, therefore the FBC alone 174 
is not sufficient in the diagnosis of ACD. 175 
Iron Studies 176 
Serum iron is reduced in ACD, reflecting the decreased availability of iron. Serum transferrin is 177 
typically normal or low, and its fall in acute inflammation is thought to be due to increased 178 
degradation36. Depending on transferrin concentration, TIBC can be low or normal. Transferrin 179 
saturation is typically low and is a reflection of the decreased serum iron. Serum ferritin is either 180 
normal or elevated, in part due to ferritin's role as an acute phase protein but also the net effect of 181 
diversion of the body's iron into this storage protein within the reticuloendothelial system in ACD. 182 
Table 1 summarises these changes. 183 
Soluble transferrin receptor (sTfR) 184 
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As previously discussed, sTfR is not affected by inflammatory cytokines and therefore can be useful 185 
in differentiating between isolated ACD (in which the concentration would be normal) and ACD 186 
associated with true iron deficiency when sTfR would be elevated. 187 
Zincprotoporphyrin (ZPP) 188 
In patients with impaired iron supply for erythropoeisis, regardless of the cause, ZPP concentrations 189 
will rise. Therefore, ZPP concentrations rise in ACD and cannot be used to assess whether there is 190 
superimposed iron deficiency37. 191 
Hepcidin 192 
Hepcidin plays a central role in the dysregulation of iron homeostasis seen in ACD. Hepcidin is 193 
usually be elevated in ACD, however the increase in production may be opposed by the effects of 194 
iron deficiency38. Therefore, concentration may be useful in distinguishing patients with pure ACD 195 
from those with superimposed iron deficiency. However, the long-term effects of hepcidin may be to 196 
induce iron deficiency and therefore its use in diagnosing ACD needs to be more carefu lly evaluated 197 
and standardised39. 198 
 199 
IRON OVERLOAD 200 
Iron overload in the setting of anaemia is commonly iatrogenic (repeated red cell transfusion in 201 
patients with thalassaemia major for example). However, it is also a well-documented phenomenon 202 
in certain diseases such as non transfusion dependent thalassaemias and sideroblastic anaemia. 203 
In iron overload, the capacity for transferrin to transport iron is exceeded; this results in an increase 204 
in non-transferrin-bound iron within the plasma, leading to direct oxidative damage to tissues and 205 
organs40. Iron accumulation in the parenchyma can lead to significant organ damage including liver 206 
cirrhosis, diabetes and myocardial damage; early diagnosis and treatment is particularly important 207 
for patients in whom iron overload is the main factor in limiting survival. 208 
While it is beyond the remit of this review to describe the pathogenesis of iron overload in these 209 
conditions, the effect of iron overload on iron studies will be discussed. 210 
Diagnosing Iron overload 211 
Typically in iron overload, iron studies show elevated ferritin, serum iron and transferrin saturation; 212 
there is a decrease in both TIBC and transferrin. A raised transferrin saturation is often an early 213 
marker of iron overload; a saturation of >45% is highly suggestive of iron overload19. Table 1 214 
summarises these changes. 215 
While there is evidence that serum ferritin concentration correlates with the degree of parenchymal 216 
loading in organs such as the liver, its accuracy can be compounded by factors such as inflammation 217 
and the underlying disease process41. Determination of liver iron concentration through biopsy is a 218 
reliable indicator of total body iron stores in patients with thalassaemia major; however this 219 
procedure is invasive42. Non invasive techniques such as MRI T2* have been shown to quantify iron 220 
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in both the liver and myocardium; MRI can be useful in diagnosing iron overload and guiding 221 
response to treatment43. 222 
SUMMARY 223 
Iron is an essential element required for growth and survival. Deficiency and dysregulation of iron 224 
homeostasis forms the basis of the two commonest causes of anaemia worldwide: iron deficiency 225 
anaemia and anaemia of chronic disease. Iron studies can be useful in the differentiation between 226 
the two disease processes and be used to guide diagnosis and treatment. 227 
 228 
Table 1 229 
 Iron Deficiency 
Anaemia 
Iron deficiency and 
inflammation 
Anaemia of chronic 
disease 
Iron overload 
Serum iron Decreased Decreased Decreased Increased 
TIBC, 
Transferrin 
Increased Decreased/Normal  Decreased/Normal Decreased 
Transferrin 
saturation 
Decreased Decreased/Normal Decreased Increased 
Serum 
ferritin 
Decreased 
(Diagnostic if 
<15μg/L) 
Normal (Usually 
<100μg/L) 
Normal/Increased Increased 
sTfR Increased Increased Normal Decreased 
ZPP Increased Increased Increased Decreased 
 230 
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